Merck & Co Inc (NYSE: MRK) Shares Are Down -18.22% Year To Date.

In the last trading session, 10.66 million Merck & Co Inc (NYSE:MRK) shares changed hands as the company’s beta touched 0.40. With the company’s per share price at $81.35 changed hands at $2.02 or 2.55% during last session, the market valuation stood at $204.27B. MRK’s last price was a discount, traded about -65.49% off its 52-week high of $134.63. The share price had its 52-week low at $73.31, which suggests the last value was 9.88% up since then.

Analysts gave the Merck & Co Inc (MRK) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.88. If we narrow down to specifics, the data shows that 0 out of 19 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MRK as a Hold, 19 felt it is a Buy and 0 rated the stock as Underweight. Merck & Co Inc’s EPS for the current quarter is expected to be 2.06.

Merck & Co Inc (NYSE:MRK) trade information

Instantly MRK was in green as seen at the end of in last trading. With action 5.46%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -18.22%, with the 5-day performance at 5.46% in the green. However, in the 30-day time frame, Merck & Co Inc (NYSE:MRK) is 7.08% up.

The consensus price target for the stock as assigned by Wall Street analysts is 94, meaning bulls need an upside of 13.46% from its current market value. According to analyst projections, MRK’s forecast low is 82 with 106 as the target high. To hit the forecast high, the stock’s price needs a -30.3% plunge from its current level, while the stock would need to soar -0.8% for it to hit the projected low.

Merck & Co Inc (MRK) estimates and forecasts

Year-over-year growth is forecast to reach 1.36% up from the last financial year.

Consensus estimates given by 16 financial analysts project the company’s revenue in the current quarter to hit an average of 15.92B. 15 analysts are of the opinion that Merck & Co Inc’s revenue for the current quarter will be 17.11B. The company’s revenue for the corresponding quarters a year ago was 16.11B and 16.66B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -1.18%. The estimates for the next quarter sales put growth at 2.75%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 12.04%. The 2025 estimates are for Merck & Co Inc earnings to increase by 16.40%, but the outlook for the next 5-year period is at 11.66% per year.

MRK Dividends

Merck & Co Inc is expected to release its next quarterly earnings report in July. The 3.88% annual yield figure for the share gives it an annual dividend of 3.16. It is important to note, however, that the 3.88% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.

Merck & Co Inc (NYSE:MRK)’s Major holders

BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.1806% or 207.3 million shares worth $25.66 billion as of 2024-06-30.

Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund. With 79.77 shares estimated at $6.49 billion under it, the former controlled 3.18% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard 500 Index Fund held about 2.80% of the shares, roughly 70.29 shares worth around $5.72 billion.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.